Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Post by HARJAYon Feb 22, 2021 9:32am
303 Views
Post# 32624963

FYI

FYICIBC World Markets analyst John Zamparo expects U.S. federal legalization of cannabis by the end of 2022.

After increasing enterprise value-to-sales multiples “to reflect the recent upward movement in sentiment,” Mr. Zamparo also raised his targets for these stocks:

Aphria Inc. (APHA-T, “outperformer”) to $28 from $18. Average: $15.70.

“While 18 times cannabis revenue is well above historical norms, we do not view it as unreasonable in the current environment for what we believe is Canada’s market share leader,” he said. “Additionally, upside potential exists purely from the implied price of the stock based on the pending deal with Tilray.”

<< Previous
Bullboard Posts
Next >>